Skip to main content
Evidence Snapshot

Aurora kinase B

CHEMBL2185 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2185
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aurora kinase B as ChEMBL target CHEMBL2185, mapped to UniProt Q96GD4. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aurora kinase B
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2185
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96GD4
Aurora kinase B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Aurora kinase B matters

As of 2026-09-13

Aurora kinase B is reviewed as Aurora kinase B (UniProt Q96GD4); Aurora kinase B shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 28 approved drugs, 5573 compounds, and 1152 assays, with lead potency reaching pChEMBL 11.0.

Disease context
small cell lung carcinoma

Aurora kinase B shows late clinical disease relevance led by small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include IBCASERTIB.

Start review with small cell lung carcinoma because it currently carries late clinical support. Linked drugs include IBCASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 28 approved drugs, 5573 compounds, and 1152 assays for this target. The dominant activity type is IC50. CHEMBL4225923 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4225923 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
28 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Aurora kinase B matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q96GD4, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why small cell lung carcinoma is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5573
Total Compounds
1152
Total Assays
28
Approved Drugs
IC50: 3247.0, KI: 1190.0, EC50: 110.0, KD: 456.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4225923
 11.0 Kd —
No preferred name
CHEMBL3680444
 10.4 IC50 —
No preferred name
CHEMBL3680508
 10.3 IC50 —
No preferred name
CHEMBL3680447
 10.3 IC50 —
No preferred name
CHEMBL3680552
 10.2 IC50 —

Approved Drugs

Structure Compound First Approval
QUIZARTINIB
CHEMBL576982
 2023
PACRITINIB
CHEMBL2035187
 2022
ENTRECTINIB
CHEMBL1983268
 2019
FEDRATINIB
CHEMBL1287853
 2019
PEXIDARTINIB
CHEMBL3813873
 2019
MIDOSTAURIN
CHEMBL608533
 2017
NINTEDANIB
CHEMBL502835
 2014
AXITINIB
CHEMBL1289926
 2012
TOFACITINIB
CHEMBL221959
 2012
CRIZOTINIB
CHEMBL601719
 2011
SUNITINIB
CHEMBL535
 2006
SORAFENIB
CHEMBL1336
 2005
ERLOTINIB
CHEMBL553
 2004
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:05:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2185